DNA (NYSE: DNA) holder plans sale of 736 Class A shares on NYSE per notice

Rhea-AI Filing Summary

Steve Coen filed a notice of proposed sale of restricted stock for the company with ticker DNA. The filing covers a planned sale of 736 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/15/2025 and an aggregate market value of $6540.02. The table lists 48523595 Class A shares outstanding.

The shares to be sold were acquired on 12/12/2025 via restricted stock vesting from the issuer as compensation. The notice also reports that in the prior three months Steve Coen sold 5609 and 1312 Class A shares on 10/01/2025 and 10/17/2025, generating gross proceeds of $84135.00 and $17907.89. By signing, the seller represents he does not know any material adverse information about the issuer’s current and prospective operations that has not been publicly disclosed and acknowledges potential federal criminal penalties for intentional misstatements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	736	6540.02	48523595	12/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	12/12/2025	Restricted Stock Vesting	Issuer			736	12/12/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	10/01/2025	5609	84135.00
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	10/17/2025	1312	17907.89

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What stock sale is disclosed in this DNA filing?

The notice covers a planned sale of 736 Class A shares of the issuer with ticker DNA, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/15/2025 and an aggregate market value of $6540.02.

How were the DNA shares being sold acquired?

The 736 Class A shares to be sold were acquired on 12/12/2025 through restricted stock vesting from the issuer, with the nature of payment described as compensation.

How many DNA Class A shares are outstanding according to this notice?

The securities information table lists 48523595 Class A shares outstanding for the issuer associated with ticker DNA.

Which broker and exchange will handle the DNA share sale?

The planned sale will be executed through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, and the shares are listed on the NYSE.

What prior sales by the seller does the DNA notice report for the past 3 months?

The past 3 months section lists Steve Coen as selling 5609 Class A shares on 10/01/2025 for gross proceeds of $84135.00, and 1312 Class A shares on 10/17/2025 for gross proceeds of $17907.89.

What representations does the seller make about material information in this DNA filing?

By signing the notice, the seller represents that he does not know any material adverse information regarding the issuer’s current and prospective operations that has not been publicly disclosed and acknowledges that intentional misstatements or omissions can constitute federal criminal violations under 18 U.S.C. 1001.

Does this DNA notice mention a Rule 10b5-1 trading plan?

The representation language notes that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, then by signing and indicating the plan or instruction date, that person makes the same representation as of that adoption or instruction date.